Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
43.11
-0.66 (-1.51%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
April 26, 2024
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
What's Going On With Pfizer Stock On Thursday?
April 25, 2024
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
April 19, 2024
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory...
Via
Benzinga
Topics
Brexit
Exposures
Brexit
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
April 18, 2024
Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a focus shift to drug development, the move seeks funding for potential...
Via
Benzinga
Peering Into GSK's Recent Short Interest
March 26, 2024
Via
Benzinga
GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
April 17, 2024
Lasting protection against shingles for adults over 50 with GSK's RZV vaccine. New data from ZOSTER-049 trial reveals over a decade of high efficacy. Plus, GSK's oral antibiotic, gepotidacin, shows...
Via
Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
April 11, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
April 08, 2024
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Via
The Motley Fool
CureVac, GS Partner Release Data On Influenza Vaccine Study
April 04, 2024
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...
Via
Benzinga
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
April 04, 2024
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
April 03, 2024
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Via
MarketBeat
Exposures
Product Safety
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
April 03, 2024
These stocks could rocket higher, but they also present significant risks.
Via
The Motley Fool
Russell 2000 Index Best And Worst Performing Stocks Of 2024
April 02, 2024
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
March 24, 2024
Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.
Via
The Motley Fool
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
March 21, 2024
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...
Via
Benzinga
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer
March 18, 2024
Latest advancements in endometrial cancer treatment with GSK's Jemperli (dostarlimab)! Explore promising overall survival and progression-free survival results from the RUBY trial, paving the way for...
Via
Benzinga
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
March 18, 2024
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon.
Via
Benzinga
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
March 16, 2024
From
GSK plc
Via
Business Wire
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
March 11, 2024
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.
Via
InvestorPlace
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
March 11, 2024
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets.
Via
Benzinga
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Via
InvestorPlace
GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study
March 07, 2024
GSK's DREAMM-8 trial reveals positive interim results for Blenrep combo in relapsed multiple myeloma. Improved progression-free survival and overall survival trend observed.
Via
Benzinga
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 07, 2024
From
GSK plc
Via
Business Wire
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
March 06, 2024
Findings from ViiV Healthcare's LATITUDE trial on long-acting HIV treatment. Cabenuva demonstrates superior efficacy in viral load suppression compared to daily oral therapy. Key secondary endpoints...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 06, 2024
Via
Benzinga
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says
March 05, 2024
WHO's latest HIV Drug Resistance Report reveals trends in drug resistance. Discover insights on dolutegravir's impact, challenges in HIVDR monitoring, and recommendations for standardized...
Via
Benzinga
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
March 04, 2024
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management.
Via
Benzinga
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars
February 29, 2024
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.